Skip to main content
AI Market Summary
Loading market intelligence...

Momenta Pharmaceuticals, Inc. (MNTA) Stock Forecast 2025 - AI Price Prediction & Analysis


Momenta Pharmaceuticals, Inc. (MNTA) AI Stock Price Forecast & Investment Analysis

Momenta Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading Momenta Pharmaceuticals, Inc. interactive price chart and technical analysis...

Momenta Pharmaceuticals, Inc. (MNTA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Momenta Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Momenta Pharmaceuticals, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Momenta Pharmaceuticals, Inc.: Momenta Pharmaceuticals, Inc. operates in the Health Technology sector, establishing it as a mid-cap growth opportunity.

Momenta Pharmaceuticals, Inc. (Stock Symbol: MNTA) is a leading company in the Health Technology sector , specifically operating within the Biotechnology industry.

The organization employs approximately 118 professionals worldwide and operates under the strategic leadership of CEO Craig A. Wheeler.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Momenta Pharmaceuticals, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Momenta Pharmaceuticals, Inc.: With $30M in annual revenue and -757.6% net margin, the company demonstrates developing profitability.

Annual Revenue: $30 million generating a -757.6% net profit margin .

Market Capitalization: $5720 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -64.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Momenta Pharmaceuticals, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Momenta Pharmaceuticals, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Momenta Pharmaceuticals, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Momenta Pharmaceuticals, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Momenta Pharmaceuticals, Inc.: Market positioning analysis based on available financial and operational metrics.

Momenta Pharmaceuticals, Inc. strategically competes in the highly dynamic Biotechnology marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy -423.7% gross margin, indicating strong pricing power and operational efficiency.

Momenta Pharmaceuticals, Inc. (MNTA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Momenta Pharmaceuticals, Inc. stock analysis.

Loading Momenta Pharmaceuticals, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Momenta Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Momenta Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Momenta Pharmaceuticals, Inc.: With a P/E ratio of -24.64, the market sees the stock as potentially undervalued.

P/E Ratio -24.64x
P/B Ratio 15.81x
Market Cap $5720M
EPS $-2.13
Book Value/Share $3.32
Revenue/Share $0.28
FCF/Share $-2.15
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Momenta Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Momenta Pharmaceuticals, Inc.: An ROE of -64.4% indicates room for improvement in shareholder value creation.

ROE -64.4%
ROA -45.4%
ROIC -54.6%
Gross Margin -423.7%
Operating Margin -815.3%
Net Margin -757.6%
EBT Margin -757.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Momenta Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Momenta Pharmaceuticals, Inc.: A current ratio of 6.38 indicates strong liquidity.

Current Ratio 6.38x
Quick Ratio 6.17x
D/E Ratio 0.08x
Financial Leverage 1.32x
Interest Coverage -142.7x
Working Capital $433M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Momenta Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Momenta Pharmaceuticals, Inc.: Free cash flow of $-202M indicates cash challenges that need attention.

Operating Cash Flow $-199M
Free Cash Flow $-202M
Capital Spending $-2M
OCF Growth YoY -95.8%
FCF/Sales -670.7%
CapEx/Sales 8.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Momenta Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Momenta Pharmaceuticals, Inc.: An asset turnover of 0.06x suggests room for improvement in asset utilization.

Asset Turnover 0.06x
Receivables Turnover 5.5x
Fixed Assets Turnover 0.5x
Days Sales Outstanding 67 days
Payables Period 18 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Momenta Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Momenta Pharmaceuticals, Inc.: With annual revenue of $30M, Momenta Pharmaceuticals, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $30M
Operating Income $-245M
Net Income $-228M
R&D Expense $23M
SG&A Expense $395M
Cost of Goods Sold $524M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 87%
Cash & Short-term Investments 83%
Total Liabilities 24%
Accounts Receivable 1%
Dividend & Shareholder Information
Shares Outstanding 109M

Latest Momenta Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Momenta Pharmaceuticals, Inc. (MNTA) stock price and investment outlook.

, source: The Pantagraph

Nevertheless, the company is pressing on highlighting other drugs in its pipeline during its third-quarter conference call and hopes that it'll be able to gain Food and Drug Administration approval ...

, source: The Telegraph

What: Momenta Pharmaceuticals was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan to develop six biosimilar products. So what: Momenta ...

Momenta Pharmaceuticals, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Momenta Pharmaceuticals, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Momenta Pharmaceuticals, Inc. Stock Forecast

How accurate are Momenta Pharmaceuticals, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for MNTA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Momenta Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Momenta Pharmaceuticals, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Momenta Pharmaceuticals, Inc. a good investment in 2025?

Based on our AI analysis, Momenta Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Momenta Pharmaceuticals, Inc. forecasts updated?

Momenta Pharmaceuticals, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Momenta Pharmaceuticals, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Momenta Pharmaceuticals, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...